Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Unveiling the life-cycles of malarial parasites to aid the routine validation of drugs and live vaccines for the disease.
  • USA - English


News provided by

Kawasaki City, Japan

Oct 27, 2015, 05:00 ET

Share this article

Share toX

Share this article

Share toX

Generation of  humanized mice engrafted with both human liver tissue and human red blood cells.
Generation of humanized mice engrafted with both human liver tissue and human red blood cells.

Kawasaki, Japan (PRWEB UK) 27 October 2015 -- Details of the life-cycles of P. falciparum and P.ovale, two of the parasites that cause malaria, are revealed by Hiroshi Suemizu at the Central Institute for Experimental Animals, Kawasaki and researchers affiliated with Kawasaki INnovation Gateway at SKYFRONT, Japan. The findings are published in Nature Communications. The researchers expect the use of humanized mice for malarial studies to aid the routine validation of drugs and live vaccines for the disease.

Further information about science and technology projects at Kawasaki City is available in the Kawasaki SkyFront iNewsletter that highlights research being conducted by scientists and industries affiliated with Kawasaki INnovation Gateway at SKYFRONT (KING SKYFRONT)—the City’s flagship science and technology hub focused on open innovation in the life sciences and environment.

KING SKYFRONT is located on the opposite side of the Tama River that separates Tokyo International Airport (also known as Haneda Airport) and the Tonomachi district of Kawasaki. The Airport plays an important role in the globalization of the innovative activities of scholars, industrialists and City administrators based at KING SKYFRONT.

October 2015 Issue of Kawasaki SkyFront iNewsletter: http://inewsletter-king-skyfront.jp/en/

Unveiling the life-cycles of malarial parasites
Malaria is caused by variants of Plasmodium parasites carried by mosquitoes, and remains a leading cause death worldwide. The strain Plasmodium falciparum triggers a very severe form of malaria, accounting for the majority of deaths. Those people infected with less virulent strain P.ovale may also suffer serious illness, but a key difference is that this particular strain has the ability to ‘lie dormant’ in the body only to reappear months, or even years, later.

Due to the parasites behaving differently in different hosts, it has proven difficult to study the parasites inside the body to verify their precise life-cycle and replication.

Now, for the first time, Valerie Soulard and co-workers at Sorbonne University, Paris, France, with an international team of scientists including Hiroshi Suemizu at the Central Institute for Experimental Animals, Kawasaki, have successfully analyzed the complete life cycle of P.falciparum in the bodies of humanized mice. They also uncovered the stages P.ovale parasites follow inside humanized mice liver cells.
Soulard and her team engrafted mice with both human liver tissues and human red blood cells, to follow the complete development of the P.falciparum parasites from early stages in liver cells, through multiplication to the appearance of mature germ cells in the blood stream.

In addition, the team discovered that, unlike P.falciparum, P.ovale parasites are able to ‘pause’ their development in the liver, maturing weeks later to trigger a relapse of the disease in the patient.
The team hope the further use of humanized mice for malarial studies will aid the routine validation of drugs and live vaccines for the disease, together with further analysis of Plasmodium strains.

Reference and affiliations
Valérie Soulard1,2,3, Henriette Bosson-Vanga1,2,3,4,*, Audrey Lorthiois1,2,3,*,w, Clémentine Roucher1,2,3, Jean- François Franetich1,2,3, Gigliola Zanghi1,2,3, Mallaury Bordessoulles1,2,3, Maurel Tefit1,2,3, Marc Thellier5, Serban Morosan6, Gilles Le Naour7, Frédérique Capron7, Hiroshi Suemizu8, Georges Snounou1,2,3, Alicia Moreno-Sabater1,2,3,* & Dominique Mazier1,2,3,5,*. Plasmodium falciparum full life cycle and Plasmodium ovale liver stages in humanized mice. Nature Communications 6 (7690) Published 24 July 2015
1. Sorbonne Universités, UPMC Univ Paris 06, CR7, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), 91 Bd de l’hôpital, F-75013 Paris, France.
2. INSERM, U1135, CIMI-PARIS, 91 Bd de l’hôpital, F-75013 Paris, France.
3. CNRS, ERL 8255, CIMI-PARIS, 91 Bd de l’hôpital, F-75013 Paris, France.
4. Université FHB, UFR SPB, Departement de Parasitologie-Mycologie, BP V 34 Abidjan, Ivory Coast.
5. AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service Parasitologie-Mycologie, Centre National de Référence du Paludisme, 83 Bd de l’hôpital, F-75013 Paris, France.
6. UPMC Univ. Paris 06, INSERM, UMS28, 105 Bd de l’hôpital, F-75013 Paris, France.
7. AP-HP, UPMC Univ. Paris 06, Groupe Hospitalier Pitié-Salpêtrière, Service d’anatomie et cytologie pathologiques, 83 Bd de l’hôpital, F-75013 Paris, France.
8. Central Institute for Experimental Animal, Kawasaki, Kanegawa, Japan.
w Present address: INSERM U1016, CNRS UMRS 8104, Institut Cochin, F-75014 Paris, France.
*corresponding author email address: valerie(dot)soulard(at)upmc(dot)fr

For the first time, researchers in France (with the help of the Central Institute for Experimental Animals, Kawasaki, Japan) have generated humanized mice engrafted with both human liver tissue and human red blood cells. The mice were then used to reveal the full life-cycle of Plasmodium falciparum, and liver stage life-cycle of Plasmodium ovale, two of the parasites that cause malaria.

Video Feature
Mamoru Takase
Senior Manager
Medical Professional Education
Johnson & Johnson K.K. Medical Company
http://inewsletter-king-skyfront.jp/en/video_feature/vol_5/feature01/

Research Highlights
Unveiling the life-cycles of malarial parasites
http://inewsletter-king-skyfront.jp/en/research_highlights/vol_5/research01/

Gadolinium-based particles show and treat tumours
http://inewsletter-king-skyfront.jp/en/research_highlights/vol_5/research02/

Maple syrup extract helps mitigate liver inflammation caused by high-fat diet
http://inewsletter-king-skyfront.jp/en/research_highlights/vol_5research03/

About KING SKYFRONT
The Kawasaki INnovation Gateway (KING) SKYFRONT is the flagship science and technology innovation hub of Kawasaki City. KING SKYFRONT is a 40 hectare area located in the Tonomachi area of the Keihin Industrial Region that spans Tokyo and Kanagawa Prefecture and Tokyo International Airport (also often referred to as Haneda Airport).

KING SKYFRONT was launched in 2013 as a base for scholars, industrialists and government administrators to work together to devise real life solutions to global issues in the life sciences and environment.

Website
http://www.city.kawasaki.jp/en/category/132-5-0-0-0-0-0-0-0-0.html

KING SKYFRONT Concept Video
https://www.youtube.com/watch?v=24Y2VFBOD8c&list=PL70Lb7fKyWsjegtd4tBfXQqbRZbeNjqwt&index=2

Further information
Kawasaki City, Japan, Coastal Area International Strategy Office
General Planning Bureau, City of Kawasaki,
1 Miyamoto-cho, Kawasaki-ku, Kawasaki-city, Kanagawa 210-8577, Japan
EMAIL: 20rinkai(at)city(dot)kawasaki(dot)jp

Naoko Sato, Kawasaki City, Japan, +81 9065213797, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.